Difference between revisions of "Maprotiline-hypericum"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = hypericum  
 
| to = hypericum  
 
| stop =  
 
| stop =  
* '''Before day 0:''' gradually reduce dosage of maprotiline to a maximum of 75 mg/day.
+
* '''Before day 1:''' gradually reduce dosage of maprotiline to a maximum of 75 mg/day.
 
* '''Day 1:''' reduce dosage of maprotiline to 50 mg/day.
 
* '''Day 1:''' reduce dosage of maprotiline to 50 mg/day.
 
* '''Day 7:''' reduce dosage of maprotiline to 25 mg/day.
 
* '''Day 7:''' reduce dosage of maprotiline to 25 mg/day.

Revision as of 14:03, 17 November 2009

Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline
Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort

Switch medication from maprotiline to hypericum.[1] [2]

Nietinrijdenbord.png Stop maprotiline
  • Before day 1: gradually reduce dosage of maprotiline to a maximum of 75 mg/day.
  • Day 1: reduce dosage of maprotiline to 50 mg/day.
  • Day 7: reduce dosage of maprotiline to 25 mg/day.
  • Day 14: stop dosage of maprotiline.
Eenrichtingbord.png Start hypericum
  • Day 14-28: a wash-out period of 2 weeks is necessary.
  • Day 28: start administration of hypericum.
Infobord.png More information
  • Hypericum induces enzymes of the CYP P-450 type and P-gp type.
  • Hypericum might have MAO-inhibiting and/or COMT-inhibiting properties.
  • Many studies reported that hypericin is the main source of pharmacological effects of hypericum. However the IC50 of hypericin to inhibit MAO A and MAO B is 100- to 1000-fold higher than accessible Cmax values of hypericin after oral administration of hypericum.[3]
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Wurglics M, Schubert-Zsilavecz M.Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.